Solvent-Free Abraxane(R) Combined With Targeted Therapy Bevacizumab Evaluated As First-Line Treatment For Metastatic Breast Cancer

June 03rd, 2008 | Category: Cancer

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE® for Injectable Suspension (paclitaxel protein-bound

particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Combination Therapy Of Solvent-Free Abraxane(R) And The Targeted Therapy Bevacizumab Evaluated As First-Line Treatment For Metastatic Breast Cancer
  • Iressa Shows Promise For Treatment Of Metastatic Breast Cancer When Combined With Hormonal Therapy
  • Second Phase III Study Of Avastin(R) (Bevacizumab) In 1st Line Metastatic Breast Cancer Meets Its Primary Endpoint
  • NICE Drug Reviews Terminated When Manufacturers Fail To Submit Evidence
  • Merck Applies To Extend Use Of Erbitux For 1st-Line Colorectal Cancer

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.